British Hospital

About: British Hospital is a healthcare organization based out in Montevideo, Uruguay. It is known for research contribution in the topics: Population & Hazard ratio. The organization has 445 authors who have published 358 publications receiving 7878 citations. The organization is also known as: British Hospital.

Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation.

Abstract: SARS-CoV-2 has spread rapidly worldwide, but the full impact of the COVID-19 pandemic on the field of hematopoietic cell transplantation (HCT) remains unknown. To understand this better, an 18-item online survey was disseminated by the Worldwide Network for Blood & Marrow Transplantation with questions exploring SARS-CoV-2 testing algorithms, mobilization, and cryopreservation strategies and COVID-19 infections in allogeneic related and autologous hematopoietic progenitor cell (HPC) donors. The aim of this survey was to assess the impact of the outbreak on policies relating to HPC mobilization, collection, and processing with respect to changes in daily routine. A total of 91 individual responses from distinct centers in 6 continents were available for analysis. In these centers, the majority (72%) of allogeneic related and autologous donors are routinely tested for SARS-CoV-2 before HPC collection, and 80% of centers implement cryopreservation of allogeneic HPC grafts before commencing conditioning regimens in patients. Five related and 14 autologous donors who tested positive for COVID-19 did not experience any unexpected adverse events or reactions during growth factor administration (eg, hyperinflammatory syndrome). These data are limited by the small number of survey respondents but nonetheless suggest that centers are following the recommendations of appropriate scientific organizations and provide some preliminary data to suggest areas of further study.

Respiratory apraxia in amyotrophic lateral sclerosis.

Abstract: Respiratory dysfunction is a critical problem in amyotrophic lateral sclerosis (ALS) We report a patient with ALS who had respiratory apraxia A 74‐year‐old female presented with progressive dysarthria and dysphagia Clinical signs and evidence of widespread denervation on electromyography (EMG) confirmed the diagnosis of ALS She had no signs of dementia Irregular volitional inspiratory movements on verbal command were noticed, in contrast with rhythmic automatic inspiration – respiratory apraxia Limb and buco‐facial movements showed no signs of apraxia EMG of respiratory muscles was normal, apart from irregular phasic activity of the diaphragm on volitional inspiration; this was confirmed by recording respiratory movements with a percutaneous sensor transducer Sleep study was normal She deteriorated rapidly; nonetheless, no clinical sign of dementia or other apraxic findings were observed ALS, particularly when of bulbar onset, can cause respiratory apraxia and EMG of the respiratory muscles can

Head tilt response: A complementary test to the Subjective Visual Vertical

Abstract: This paper studies the phenomenon of the perceived vertical by means of a novel dynamic experiment. This task is inspired in the Subjective Visual Vertical test and can be regarded as complementary in terms of how the information involved varies (visual, otolithic and neck proprioception). The experiment consists in presenting a white stripe in a pair of virtual reality goggles and adjusting the roll angle of the head until the stripe is aligned with the gravitational vertical. The roll angle of the head is measured and recorded along each trial where the white stripe changes position four times, after a specific amount of time. The task was run on a group of 28 normal subjects and a small sample of 5 patients with vestibular hypofunction. Six parameters derived from Control Theory were extracted from the data to characterize the subject transient response. All parameters for normal subjects were found to be normally distributed. Experimental results show that discrimination is possible between normal subjects and patients using just one or two of the parameters studied.

NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).

Abstract: Gemcitabine/cisplatin is standard of care for first-line treatment of patients with advanced biliary tract cancer (aBTC); new treatments are needed. NUC-1031 is designed to overcome key cancer resistance mechanisms associated with gemcitabine. The tolerability/efficacy signal of NUC-1031/cisplatin in the Phase Ib ABC-08 study suggested that this combination may represent a more efficacious therapy than gemcitabine/cisplatin for patients with aBTC, leading to initiation of the global NuTide:121 study which will include 828 patients ≥18 years with untreated histologically/cytologically-confirmed aBTC (including cholangiocarcinoma, gallbladder or ampullary cancer); randomized (1:1) to NUC-1031 (725 mg/m2)/cisplatin (25 mg/m2) or gemcitabine (1000 mg/m2)/cisplatin (25 mg/m2), on days 1/8, Q21-days. Primary objectives are overall survival and objective response rate. Secondary objectives: progression-free survival, safety, pharmacokinetics, patient-reported quality of life and correlative studies. (Investigational new drug (IND) number: 139058, European Clinical Trials database: EudraCT Number 2019-001025-28, ClinicalTrials.gov identifier: NCT04163900).